Jim Nonomiya
Overview
Explore the profile of Jim Nonomiya including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
41
Citations
829
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Nonomiya J, Li K, Babin B, Mulvihill M
Anal Chem
. 2023 Jan;
95(7):3779-3788.
PMID: 36706310
Interest in covalent drug discovery has surged in recent years, following the high-profile FDA approvals of covalent inhibitors that target BTK and KRAS G12C. High-throughput screening by intact protein mass...
2.
Barreira da Silva R, Leitao R, Pechuan-Jorge X, Werneke S, Oeh J, Javinal V, et al.
Nat Immunol
. 2022 Mar;
23(4):568-580.
PMID: 35314846
Tumor-associated macrophages are composed of distinct populations arising from monocytes or tissue macrophages, with a poorly understood link to disease pathogenesis. Here, we demonstrate that mouse monocyte migration was supported...
3.
Li K, Quinn J, Saabye M, Guerrero J, Nonomiya J, Lian Q, et al.
Anal Chem
. 2022 Jan;
94(2):1230-1239.
PMID: 34990117
With recent advances and success in several drugs designed to treat acute and chronic diseases, targeted covalent inhibitors show a resurgence in drug discovery. As covalent inhibition is time-dependent, the...
4.
Sternicki L, Nonomiya J, Liu M, Mulvihill M, Quinn R
ChemMedChem
. 2021 Apr;
16(14):2206-2210.
PMID: 33792163
PROteolysis TArgeting Chimeras (PROTACs) promote the degradation, rather than inhibition, of a drug target as a mechanism for therapeutic treatment. Bifunctional PROTAC molecules allow simultaneous binding of both the target...
5.
Liu X, Liang X, LeCouter J, Ubhayakar S, Chen J, Cheng J, et al.
Drug Metab Dispos
. 2020 Mar;
48(5):408-419.
PMID: 32132091
The objectives of the present study were to characterize GNE-947 for its phosphoinositide 3-kinase (PI3K) and mammalian target of rapamycin (mTOR) inhibitory activities, in vitro anti-cell migration activity in human...
6.
Zak M, Hanan E, Lupardus P, Brown D, Robinson C, Siu M, et al.
Bioorg Med Chem Lett
. 2019 Apr;
29(12):1522-1531.
PMID: 30981576
Disruption of interleukin-13 (IL-13) signaling with large molecule antibody therapies has shown promise in diseases of allergic inflammation. Given that IL-13 recruits several members of the Janus Kinase family (JAK1,...
7.
Joseph J, Darimont B, Zhou W, Arrazate A, Young A, Ingalla E, et al.
Elife
. 2019 Jan;
8.
PMID: 30614786
No abstract available.
8.
Wei B, Gunzner-Toste J, Yao H, Wang T, Wang J, Xu Z, et al.
J Med Chem
. 2017 Dec;
61(3):989-1000.
PMID: 29227683
Antibody-drug conjugates (ADCs) have become an important therapeutic modality for oncology, with three approved by the FDA and over 60 others in clinical trials. Despite the progress, improvements in ADC...
9.
Safina B, Elliott R, Forrest A, Heald R, Murray J, Nonomiya J, et al.
ACS Med Chem Lett
. 2017 Sep;
8(9):936-940.
PMID: 28947940
A novel selective benzoxazepin inhibitor of PI3Kδ has been discovered. Beginning from compound , an αPI3K inhibitor, we utilized structure-based drug design and computational analysis of dihedral torsion angles to...
10.
Joseph J, Darimont B, Zhou W, Arrazate A, Young A, Ingalla E, et al.
Elife
. 2016 Jul;
5.
PMID: 27410477
ER-targeted therapeutics provide valuable treatment options for patients with ER+ breast cancer, however, current relapse and mortality rates emphasize the need for improved therapeutic strategies. The recent discovery of prevalent...